

Supplementary Table 1. Baseline characteristics of patients (placebo vs. escitalopram)

Characteristic	Baseline-Pink			Baseline-Blue		
	Placebo (n=109)	Escitalopram (n=94)	<i>P</i>	Placebo (n=128)	Escitalopram (n=147)	<i>P</i>
At baseline						
Age (yr)	63.0±12.5	61.7±11.8	0.452	64.9±11.3	65.4±12.7	0.746
Female sex	32 (29.4)	31 (33.0)	0.578	54 (42.2)	70 (47.6)	0.367
Hypertension	80 (73.4)	76 (80.9)	0.209	97 (75.8)	107 (72.8)	0.572
Diabetes	47 (43.1)	31 (33.0)	0.139	55 (43.0)	71 (48.3)	0.376
Hyperlipidemia	57 (52.3)	41 (43.6)	0.217	62 (48.4)	75 (51.0)	0.669
Coronary artery disease	12 (11.0)	12 (12.8)	0.699	18 (14.1)	21 (14.3)	0.958
Smoking	59 (54.1)	53 (56.4)	0.747	51 (39.8)	67 (45.6)	0.338
Lesion side			0.097			0.739
Right	55 (50.5)	40 (42.6)		70 (54.7)	74 (50.3)	
Left	45 (41.3)	51 (54.3)		49 (38.3)	63 (42.9)	
Both	9 (8.3)	3 (3.2)		9 (7.0)	10 (6.8)	
Clinical variables						
MADRS	3.6±2.3	3.2±2.5	0.320	16.6±6.7	15.5±6.7	0.222
NIHSS	4.2±2.6	4.2±2.1	0.922	5.2±3.0	5.3±3.2	0.686
Emotional incontinence	6 (5.5)	0	0.021	12 (9.4)	14 (9.5)	0.966
Anger proneness	22.9±5.1	22.1±5.7	0.278	23.2±5.6	22.6±6.1	0.405
MoCA	20.0±6.4	19.6±6.6	0.656	18.1±6.9	16.8±7.2	0.145

Values are presented as mean±standard deviation or number (%).

MADRS, Montgomery-Asberg Depression Rating Scale; NIHSS, National Institute of Health Stroke Scale; MoCA, Montreal Cognitive Assessment.